Rubella (German Measles) - Pipeline Review, H2 2020
Rubella (German Measles) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella - Pipeline Review, H2 2020, provides an overview of the Rubella (Infectious Disease) pipeline landscape.
Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rubella (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rubella (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III stages comprises 2 molecules, respectively.
Rubella (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella - Pipeline Review, H2 2020, provides an overview of the Rubella (Infectious Disease) pipeline landscape.
Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rubella (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rubella (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III stages comprises 2 molecules, respectively.
Rubella (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rubella (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rubella (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Rubella (German Measles) - Overview
Rubella (German Measles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rubella (German Measles) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Rubella (German Measles) - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Micron Biomedical Inc
Sinovac Biotech Ltd
Univercells SA
Vaxxas Inc
Zhongyianke Biotech Co Ltd
Rubella (German Measles) - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rubella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rubella (German Measles) - Dormant Projects
Rubella (German Measles) - Product Development Milestones
Featured News & Press Releases
Sep 01, 2020: Micron Biomedical progresses with clinical evaluation of its technology for measles-rubella vaccination
Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Rubella (German Measles) - Overview
Rubella (German Measles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rubella (German Measles) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Rubella (German Measles) - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Micron Biomedical Inc
Sinovac Biotech Ltd
Univercells SA
Vaxxas Inc
Zhongyianke Biotech Co Ltd
Rubella (German Measles) - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rubella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rubella (German Measles) - Dormant Projects
Rubella (German Measles) - Product Development Milestones
Featured News & Press Releases
Sep 01, 2020: Micron Biomedical progresses with clinical evaluation of its technology for measles-rubella vaccination
Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Rubella (German Measles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Rubella (German Measles) - Pipeline by Biological E Ltd, H2 2020
Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H2 2020
Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, H2 2020
Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2020
Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H2 2020
Rubella (German Measles) - Pipeline by Micron Biomedical Inc, H2 2020
Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H2 2020
Rubella (German Measles) - Pipeline by Univercells SA, H2 2020
Rubella (German Measles) - Pipeline by Vaxxas Inc, H2 2020
Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, H2 2020
Rubella (German Measles) - Dormant Projects, H2 2020
Number of Products under Development for Rubella (German Measles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Rubella (German Measles) - Pipeline by Biological E Ltd, H2 2020
Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H2 2020
Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, H2 2020
Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2020
Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H2 2020
Rubella (German Measles) - Pipeline by Micron Biomedical Inc, H2 2020
Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H2 2020
Rubella (German Measles) - Pipeline by Univercells SA, H2 2020
Rubella (German Measles) - Pipeline by Vaxxas Inc, H2 2020
Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, H2 2020
Rubella (German Measles) - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Rubella (German Measles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Rubella (German Measles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
